- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00348946
Androgen Effect on Klinefelter Syndrome Motor Outcome
Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Klinefelter syndrome (KS), a genetic disorder that affects males only, is characterized by having an extra X chromosome. The phenotype - or physical and learning features - includes testicular failure, tall stature, and specific cognitive and behavioral attributes such as diminished motor function, language-based learning difficulties, poor self-image, and shyness. The KS phenotype may be the result of androgen deficiency in utero, infancy, and childhood. For individuals with KS, androgen replacement is standard treatment in adolescence and adulthood but has not been used earlier in childhood or included in the standard medical care of KS children ages 4 to 12.
The purpose of this study is to examine the effects of androgen on learning and development in boys with KS. Researchers also want to determine if low-dose androgen replacement at an early age will improve some of the learning difficulties associated with the disorder. The overall goal of this study is to address questions regarding the relationship of early androgen deficiency to learning and motor function.
Participants in the study will be randomized to one of two treatment groups, receiving either oxandrolone (low-dose androgen) or placebo, for two years. All participants will be evaluated for safety at the beginning of the study and at 3, 6, 12, 18, and 24 months. Also at the beginning of the study and every 3 to 6 months thereafter (for a total of 6 visits), the researchers will perform a careful history and physical examination and a bone age X-ray, and obtain a blood sample.
Participation in the trial will last two years and includes 6 clinic visits.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University, Department of Pediatrics, 1025 Walnut Street, Suite 726
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Karyotype diagnosis of Klinefelter syndrome
- Chronological age of 4-12 years
- No treatment with androgen in the past year
Exclusion Criteria:
- Major liver, kidney or other systemic disease
- Variant karyotypes including 47,XYY males
- Evidence of spontaneous onset of puberty, defined as testicular size > 4ml
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Oxandrolone
Androgen oxandrolone: Oxandrolone, 0.6 > mg/kg/day, orally, for 2 years.
|
Oxandrolone ,06 >mg/kg/day, orally, for 2 years
|
PLACEBO_COMPARATOR: Placebo
An inactive substance.
|
an inactive substance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor Function/Strength
Time Frame: 2 years per subject
|
Outcome measures were tested using the following assessments: Bruininks-Osertesky Test of Motor Proficiency (BOT) subscales of (1) Visual Motor Control, (2) Upper limb Speed, and (3) Strength, Physical and Neurological Evaluation for Soft Signs (PANESS), and Hand Strength Dynamometer.
BOT assess the child's motor development and includes standard scores (mean=100, SD=15) and subtest scores and is normed for sex and age (4-14.5 years).
PANESS assesses the time required to press thumb to 4 fingers 20 times for the dominant and nondominant hands and includes standard scores (mean=100, SD=15) with age-specific norms (4-18 years).
Hand strength dynamometer assess hand strength in the dominant and nondominant hands and includes standard scores (mean=100, SD=15).
Data is expressed as standard scores with mean of 100 and SD of 15.
The minimum standard score is 50; the maximum standard score is 145.
Higher scorers imply better function.
|
2 years per subject
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive Function and Language
Time Frame: 2 years per subject
|
Outcome measures were tested using the Differential Ability Scales - 2nd edition (DAS-II).
DAS-II provides an age- and sex-standardized assessment of intellectual functioning (General Concept Ability subscale similar to IQ) in children ages 2-17 years of age (mean=100, SD=15).
The Verbal Cluster measures the child's ability to define words and perform verbal reasoning tasks.
The Nonverbal Cluster measures the child's inductive and sequential reasoning abilities.
The Spatial Cluster measures visuospatial construction ability, spatial memory, and spatial reasoning.
Data is expressed as standard scores with mean of 100 and SD of 15.
The minimum standard score is 50; the maximum standard score is 145.
Higher scores imply better function.
|
2 years per subject
|
Working Memory/Attention
Time Frame: 2 years per participant
|
Outcome measures were tested using the following cognitive assessments: Digit Span Backward, A Neuropsychological Assessment (NEPSY) subscales of (1) Phonemic Fluency and (2) Semantic Fluency, and Connors' Continuous Performance Test (CPT-II) subscales (1) Omissions, (2) Commissions, (3) Hit Reaction, (4) Variability, and (5) Preservations.
Digit Span Backward tests working memory and is normed for children ages 5-16 years.
Phonemic Fluency measures the number of words that the child can name beginning with the letters F and S (ages 6-12).
Semantic Fluency measures the number of words the child can name in the categories food and drink (ages 4-12).
CPT-II measures the ability to maintain attention over an extended period of time.
All scores are reported as standard scores with a mean of 100 and SD of 15.
The minimum standard score is 50; the maximum standard score is 145.
Higher scores imply better function.
|
2 years per participant
|
Psychosocial and Behavior Domain
Time Frame: 2 years per participants
|
Outcome measures were tested using the following social assessments: The Child Behavior Checklist (CBCL) and The Children's Depression Inventory (CDI).
The CBCL is standardized measure of behavior problems and social competency normed for children ages 4-16.
Higher scores indicate more problems, with the cutoff for the clinical range at a t score greater than or equal to 67.
The CDI assess cognitive, affective and behavioral signs of depression in children ages 6-17.
The CDI total score reflects the presence of overall depressive symptoms.
All scores are expressed as t-scores with a mean of 50 and SD of 10.
Lower scores imply better function and higher scores indicate more problem behaviors.
|
2 years per participants
|
Psychosocial and Behavior Domain
Time Frame: 2 years per subject
|
Outcome measures were tested using The Piers-Harris Self Concept Scale.
Scoring provides a total standard score and scores on six subscales: physical appearance and attributes, freedom from anxiety, intellectual and school status, behavioral adjustment, happiness and satisfaction, and popularity.
Subscales are summed and standardized to provide the total standard score with a mean of 100 and SD of 15.
The minimum standard score is 50; the maximum standard score is 145.
Higher scores imply better function.
|
2 years per subject
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Davis SM, Lahlou N, Cox-Martin M, Kowal K, Zeitler PS, Ross JL. Oxandrolone Treatment Results in an Increased Risk of Gonadarche in Prepubertal Boys With Klinefelter Syndrome. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3449-3455. doi: 10.1210/jc.2018-00682.
- Ross JL, Kushner H, Kowal K, Bardsley M, Davis S, Reiss AL, Tartaglia N, Roeltgen D. Androgen Treatment Effects on Motor Function, Cognition, and Behavior in Boys with Klinefelter Syndrome. J Pediatr. 2017 Jun;185:193-199.e4. doi: 10.1016/j.jpeds.2017.02.036. Epub 2017 Mar 10.
- Davis S, Lahlou N, Bardsley M, Temple MC, Kowal K, Pyle L, Zeitler P, Ross J. Gonadal function is associated with cardiometabolic health in pre-pubertal boys with Klinefelter syndrome. Andrology. 2016 Nov;4(6):1169-1177. doi: 10.1111/andr.12275. Epub 2016 Sep 16.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Endocrine System Diseases
- Disease
- Gonadal Disorders
- Disorders of Sex Development
- Urogenital Abnormalities
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Chromosome Disorders
- Sex Chromosome Disorders
- Sex Chromosome Disorders of Sex Development
- Hypogonadism
- Syndrome
- Klinefelter Syndrome
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anabolic Agents
- Androgens
- Oxandrolone
Other Study ID Numbers
- R01NS050597-01A2 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Klinefelter Syndrome
-
University Hospital MuensterCompletedKlinefelter Syndrome, Hypogonadism
-
Lenetix Medical Screening LaboratoryUnknownDown Syndrome (Trisomy 21) | Edward's Syndrome (Trisomy 18) | Patau Syndrome (Trisomy 13) | Klinefelter Syndrome (47, XXY) | and Other Chromosome | Abnormalities.United States
-
University of Colorado, DenverNational Institute of Neurological Disorders and Stroke (NINDS); Children's... and other collaboratorsCompletedKlinefelter Syndrome | XXY SyndromeUnited States
-
Hospices Civils de LyonCompletedKlinefelter SyndromeFrance
-
University of PittsburghTerminated
-
Odense University HospitalAarhus University Hospital; University of CopenhagenCompleted
-
University of Colorado, DenverRecruitingKlinefelter Syndrome | Trisomy X | XYY Syndrome | XXXY and XXXXY Syndrome | Xxyy Syndrome | Xyyy Syndrome | Xxxx Syndrome | Xxxxx Syndrome | Xxxyy Syndrome | Xxyyy Syndrome | Xyyyy Syndrome | Male With Sex Chromosome MosaicismUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingKlinefelter SyndromeUnited States
-
University of Colorado, DenverCompletedKlinefelter SyndromeUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States